The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.
Laurence Albigès(Université Paris-Saclay), Toni K. Choueiri(Harvard University), Sumanta K. Pal(City of Hope), Ulka N. Vaishamayan(Wayne State University), Georg A. Bjarnason(Sunnybrook Health Science Centre), Jae‐Lyun Lee(Ulsan College), Wanling Xie(Dana-Farber Cancer Institute), Konstantinos Koutsoukos(Therapeutics Clinical Research), Eunyoung Cho(Harvard University Press), D. Scott Ernst, André P. Fay(Hospital São Lucas da PUCRS), Lori Wood(Dalhousie University), Takeshi Yuasa(Japanese Foundation For Cancer Research), Mark Preston(University of Utah), Sandy Srinivas(Stanford University), Neeraj Agarwal(University of Utah), Sun Young Rha(Yonsei University), Daniel Yick Chin Heng(University of Calgary), Brian I. Rini(Vanderbilt University Medical Center)
Cited by 8
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k